Sustained Impulsive Structure → Secular Uptrend (Mature Phase) Trend: Uptrend | Location: Upper Zone | Behaviour: Corrective Structure assessed from earliest reliable data Secular advance → sustained impulsive structure Showing corrective behaviour after advance Part of the S&P 500 Structural Census. For educational purposes. Structural market observation. Structure → Level → Trigger → Probability #NF750Census #MarketStructure #UNH

Hello There, welcome to my new analysis about UNH on the weekly timeframe perspective. In recent times the stock crashed massively towards the downside. More than $300 billion of market cap has been evaporated, which resulted in massive selling pressure and heavy bearish volume. In such cases the possibility is enormously high that such a bearish downside pressure will not just reverse and turn bearish again. When looking at my chart, we can watch there how UNH is trading within this crucial descending channel formation. Within this formation, the upper boundary serves as a massive resistance. From there on, UNH already set up the -62% bearish dump towards the downside. Right now, the price of UNH is already approaching this upper boundary again. There is a high chance that it remains resistance, and UNH pulls back from there on. What is more important within this whole dynamic is the pivotal bear flag formation UNH is forming. This is a major bearish continuation formation. It will continue in the bearish direction once it has been completed, and it usually does not invalidate into the other direction. Right now, UNH is already completing the wave count within this whole formation. After this wave count, the whole formation will complete with a breakdown below the lower boundary. UNH also has several other resistances within this whole structure. As marked in my chart, UNH has a crucial resistance cluster consisting of the horizontal resistance, the resistance determined by the 500-MA marked in red, and the resistance of the upper boundary. Once UNH pulls back from this resistance, moves towards the downside, and completes the bear flag, it will activate the bearish target zones as marked in my chart. In this manner, thank you a lot for watching! I highly appreciate the support. VP

Can the recent earnings push UNH higher? Here’s what the chart is telling me today: - Broke out of a weekly down trend. - Large double bottom “W” has formed, and marking its move to the neckline. $471 is the measured move once UNH breaks the neckline here. Entry (two options): 1. Wait for a neckline break and restest of $363.56; then enter long. 2. Front run now and capture larger move. Homerun is the full move to $471. With this being on the weekly; this will 100% be a swing trade. Looking for June or July exp. -> $400 strike. Exit would be a weekly close back below neckline. You can manage and monitor this play on the daily or 4H. Happy trading.

UnitedHealth Group just printed its strongest quarterly beat in two years. Q1 2026 EPS came in at $7.23 — beating Wall Street's $6.65 estimate by 9%. The company also raised its full-year profit outlook to more than $18.25 per share (up from $17.75). Revenue hit $111.72 billion. The stock gapped 8.88% at the open, reclaiming its year-to-date breakeven in a single session. This is not just a beat — it is a structural reset. Macro Context The key driver behind the beat: UNH's medical benefit ratio came in at 83.9%, far better than the 85.5% analysts expected. That means UnitedHealth is collecting more in premiums than it is paying out in claims — a margin story, not just a revenue story. On top of that, CMS finalized a 2.48% average payment rate increase for 2027 Medicare Advantage (versus the nearly flat 0.09% proposal that had scared the sector all year). That regulatory tailwind alone is worth multiple turns of multiple expansion. Three analysts raised price targets today: Morgan Stanley named UNH a Top Pick at $375. Jefferies raised to $373. Piper Sandler hiked to $430. Technical Analysis UNH has spent 6 months in a painful drawdown from its $510 ATH (Aug 2024) all the way to $245 in March 2026 — a 52% peak-to-trough decline that priced in a worst-case regulatory and medical cost scenario. Today's earnings print confirms the worst-case did not happen. The gap-up from $324 to $352 breaks above the January 2026 consolidation zone at $340-$355, which is now the entry zone. The 200-day SMA is declining near $370 — reclaiming it would be the next major technical confirmation signal. RSI on the daily has reset from 28 (oversold) to 62 — plenty of room before overbought. Key levels: Stop: $316 — below the gap-open support and the pre-earnings close. If price fills the gap completely, the thesis is wrong. Entry zone: $340–$355 — current trading range, gap consolidation base. TP1: $375 — Morgan Stanley and Jefferies consensus target, 200-day SMA reclaim. TP2: $400 — round number, pre-correction resistance level. TP3: $430 — Piper Sandler bull-case target, measured recovery from the 2026 lows. Trade Plan Direction: Long Entry: $340–$355 Stop: $316 Target 1: $375 (R:R 1:1.4) Target 2: $400 (R:R 1:2.2) Target 3: $430 (R:R 1:3.3) Timeframe: 4–10 weeks Risk / Invalidation Thesis breaks if UNH fills the earnings gap back below $320 on a daily close — that signals institutions are selling into the strength and the beat was already priced in. Also watch for any CMS policy reversal or surprise medical cost spike in the coming weeks. Educational Takeaway Earnings gap-ups on high-quality defensive names like UNH are among the most reliable post-event setups in the market. The key distinction: was the gap on BEAT + RAISE + CATALYST SHIFT? If yes, the gap is a new base, not a fade target. UNH today checks all three boxes — beat, raised guidance, AND a regulatory tailwind that changes the multi-year earnings trajectory. That combination makes this a buy-the-gap, not sell-the-gap setup.

After a brutal 60% decline from 600$ to 240$, UNH is printing one of the rarest and most powerful reversal patterns in technical analysis - a textbook Diamond Bottom. The structure: a broadening phase capturing peak uncertainty at the lows, followed by a converging phase as buyers took control of supply - four clean touches, four clean lines, exactly by the book. Today's breakout: +8.88% on 18.49M volume with an upside gap above the diamond's upper trendline. Classic bullish confirmation. Targets: measured move (diamond depth ~$140 from breakout) = first target $490. Long-term target - full gap fill back to 600$.

Primary Scenario We primarily see the countermove as a recovery, with a high expected above resistance at $389.98, before the stock turns back down toward the larger correction low. Alternative Scenario ADJUSTMENTS: Alternatively, the stock could sell off sharply and fail to establish a new intermediate high. This path would be confirmed by a drop below support at $234.60, which would likely coincide with a move into our Long-Term Entry Range ($213.19–$119.43) (probability: 35%). Long-Term Outlook In the Wave 5, a move down below support at $234.60 is likely, during which our Entry Range ($213.19–$119.43) should be reached. We then expect prices to rise sustainably. Alternatively, the price could break through resistance at $437.70 directly and only then complete the final downward leg of the major correction. Based on the weekly chart, after moving through our Entry Range ($213.19–$119.43), the stock should ultimately target new highs above $762.66. We also see the possibility that a bottom has already been established. In that case, our Entry Range ($213.19–$119.43) would be obsolete, and we would expect a direct breakout above resistance at $762.66 (probability: 32%).

**💡 UNH (UnitedHealth Group) — Q1 Earnings Beat + Guidance Raise: Healthcare Bellwether Signals Strong Rebound** **SECTION 1 — Executive Summary** 💼 UnitedHealth Group delivered a decisive Q1 2026 earnings beat with adjusted EPS of $7.23 (versus ~$6.57 consensus) and revenue of $111.7 billion (+2% YoY), while raising full-year 2026 adjusted EPS guidance to >$18.25 amid disciplined pricing, cost controls, and Optum optimization. This mega-cap healthcare leader offers compelling value as it navigates medical cost pressures and regulatory scrutiny with a clear path to margin recovery and diversified growth. Overall rating: Buy. 12-month price target: $360 (blended DCF/comps methodology using normalized medical loss ratios and Optum contribution). The single biggest reason to own this stock right now is UnitedHealth’s unmatched scale across insurance and services (Optum), positioning it to capture long-term healthcare spending tailwinds while executing a proven turnaround plan. The single biggest risk remains elevated medical costs and Medicare Advantage reimbursement dynamics. **SECTION 2 — Business Overview** 🏢 UnitedHealth Group is the largest healthcare company in the United States, operating through two primary platforms: UnitedHealthcare (insurance and benefits) and Optum (health services, pharmacy care, and technology). Revenue breakdown (FY 2025): UnitedHealthcare ~77% (insurance premiums and fees), Optum ~23% but with higher margins and faster growth in value-based care, PBM, and data/analytics (sourced from company FY 2025 results released Jan 27 2026). Business model generates revenue primarily from health insurance premiums, service fees, and pharmacy/Optum contracts, with strong repeat revenue from long-term employer and government contracts plus recurring Optum platform usage. Competitive moat derives from massive scale (serving ~50 million via UnitedHealthcare and 123+ million via Optum in 2025), proprietary data assets, integrated care delivery, and network effects that are extremely difficult for competitors to replicate at similar efficiency. **SECTION 3 — Financial Deep Dive** 📈 Key metrics (Q1 2026 reported April 21 2026; FY 2025 from Jan 27 2026 release; TTM derived from quarterly data): Revenue: $111.7 billion (Q1 2026, +2% YoY); FY 2025 $447.6 billion (+12% YoY). Net income: Implied from EPS; Q1 GAAP EPS $6.90. EPS (adjusted): $7.23 (Q1 2026, beat by ~66 cents). Margins: Medical care ratio pressured but stabilizing; operating margin recovering. Free cash flow: Strong at $8.9 billion in Q1 2026 (1.4x net income). YoY growth rates: Revenue +2% (Q1); FY 2025 revenue +12%. Balance sheet health: Debt-to-capital ratio 42.9% (March 31 2026); cash flow supportive of leverage targets. Cash flow quality: Operating cash flow consistently exceeds net income (1.4-1.5x ratio). Capital allocation: Focus on R&D/AI investments (~$1.5 billion planned 2026), debt reduction to ~40% target, dividends, and selective M&A while resuming buybacks in H2 2026. **SECTION 4 — Growth Analysis** 🚀 Total addressable market (TAM): U.S. healthcare spending projected to exceed $6 trillion by 2030 (CMS estimates via industry reports). Current market share: Leading position in Medicare Advantage and commercial insurance; Optum dominant in PBM and value-based care. Key growth drivers next 3-5 years: Optum expansion in AI-enabled care, pharmacy services, and data analytics; UnitedHealthcare focus on employer and government segments with pricing discipline. Management raised 2026 guidance post-Q1 beat, signaling more bullish outlook than prior consensus; growth increasingly organic through technology leverage and portfolio optimization rather than acquisition-dependent. **SECTION 5 — Valuation** 📊 DCF analysis: Base case assumes mid-single-digit revenue CAGR, expanding operating margins to 5.5%+, WACC ~9%, terminal growth 3% . Implied value supports $360 target. Comparable company analysis (peers as of April 2026): CI ~12-14x forward P/E; ELV, HUM, CNC at 10-13x; UNH trades at premium but justified by scale. Historical valuation range (5-year): Forward P/E 18-25x. Bull target $420 (accelerated Optum AI gains); Base $360; Bear $280 (prolonged cost pressures). Current price ~$280-300 offers 20-30% upside to base target. **SECTION 6 — Risk Analysis** ⚠️ 1. Medical cost trend escalation (high probability/medium impact): Triggered by utilization spikes; watch quarterly medical loss ratio updates. 2. Regulatory changes in Medicare Advantage (medium-high): Reimbursement cuts or policy shifts; monitor CMS announcements. 3. Optum contract losses or margin compression (medium): Strategic exits noted; track segment earnings. 4. Cyber or operational disruptions (medium): Legacy from 2024-2025 events; monitor investment disclosures. 5. Macro healthcare spending slowdown (low-medium): Economic factors; watch employment data. Short interest low; insider activity shows typical patterns with no major red flags. No new accounting quality flags noted in latest filings. **SECTION 7 — Catalyst Calendar** 📅 Next earnings date: Already reported Q1 on April 21 2026 (conference call today at 8:00 AM ET). Upcoming events: Optum AI and technology updates throughout 2026; potential Medicare bid outcomes. Macro events: Federal budget/health policy decisions impacting reimbursement. 12-month timeline: Q2 earnings July 2026, continued membership adjustments, and leverage reduction milestones. **SECTION 8 — Technical Analysis** 📈 Primary Chart: Daily timeframe, 1-year view shows UNH consolidating in the $270-300 zone after 2025-2026 volatility, with today’s post-earnings reaction pushing toward recent highs. Price action recently crossed above the 50-day moving average while holding above key support; RSI (14) moving out of oversold territory with bullish MACD crossover and expanding volume. Major support zone $260-270, resistance $310-320. Visible setup: Potential inverse head-and-shoulders base with higher lows since February. Technical implication: Bullish bias confirmed by earnings catalyst with room for near-term continuation if volume sustains. **SECTION 9 — The Verdict** 🏆 Bull case ($420 target, 30 percent probability): Faster-than-expected margin recovery and Optum AI acceleration drive re-rating. Base case ($360 target, 50 percent probability): Steady execution on guidance with controlled medical costs. Bear case ($280 target, 20 percent probability): Persistent cost pressures or regulatory headwinds cap upside. Expected value calculation: Probability-weighted price target = $366. Final recommendation: Buy with High conviction. The 30-second elevator pitch: UnitedHealth just proved it can deliver despite industry challenges — with a Q1 beat, raised guidance, and unmatched scale across insurance and services, the stock offers attractive risk/reward as healthcare spending grows and margins normalize. **Sources** UnitedHealth Group press release April 21 2026 (Q1 2026 results); company FY 2025 results Jan 27 2026; Reuters/Seeking Alpha/Zacks earnings coverage April 21 2026; Yahoo Finance/TradingView charts and data as of April 21 2026; CMS healthcare spending projections. What are your thoughts on UNH? Drop them below 👇 #UNH #UnitedHealth #HealthcareStocks #Q1Earnings #EarningsBeat #Optum #MedicareAdvantage #StockMarket #HealthcareTurnaround #BuyTheDip

Current Price: 324.63 (Analysis was generated on Monday Morning) Direction: LONG Confidence level: 45%(YouTube trader commentary shows caution rather than bearishness while X sentiment leans slightly bullish and valuation commentary suggests rebound potential after a major selloff.) Targets Target 1: 336 Target 2: 348 Stop Levels Stop 1: 314 Stop 2: 304 Key Insights: Here's what's driving this setup. UnitedHealth has experienced a dramatic correction from its previous highs, which caught the attention of traders looking for value in large-cap healthcare. The big theme I’m seeing across commentary is that the business fundamentals remain strong even while the stock price dropped sharply. When a company with strong cash flow and dominant market share pulls back this much, traders start watching for rebound trades. Another factor is positioning ahead of earnings. Several professional traders noted they are waiting for the earnings reaction before committing long-term capital, which tells me the market is cautious. But cautious markets can also create short-term bounce opportunities when sentiment becomes too negative. On the social side, traders on X are leaning slightly bullish. Many of the posts I tracked describe the recent selloff as an overreaction, with some traders pointing out that UnitedHealth still maintains strong margins and industry leadership through its Optum and UnitedHealthcare divisions. Recent Performance: The price action tells the story clearly. UnitedHealth previously traded as high as the mid-$600s within the past year before collapsing toward the $230–$260 range. Even after the recent bounce, the stock remains dramatically below its historical highs. That kind of drawdown often attracts dip buyers in large-cap defensive sectors like healthcare. Over the last few sessions the stock has started stabilizing, and traders are watching whether buyers step in ahead of the next earnings release. If momentum continues building, short-term upside toward the mid-$330s is realistic. Expert Analysis: Several professional traders highlighted that they are not aggressively buying yet, preferring to wait for earnings confirmation. That cautious stance actually tells me something important: the market hasn’t fully crowded into the long trade yet. When positioning is light, even modest positive news can push price higher quickly. Meanwhile, trader sentiment across X shows a modest bullish tilt. I’m seeing multiple posts framing the current valuation as attractive compared with historical multiples. With a forward P/E around the mid-teens and strong free cash flow, some traders believe the risk-reward favors upside in the short term. News Impact: Recent headlines focus on two competing forces. On one hand, UnitedHealth launched its AI health companion “Avery,” which signals ongoing investment in digital healthcare services. On the other hand, regulatory scrutiny and healthcare policy risks continue to hang over the sector. Interestingly, despite those concerns, analysts still maintain price targets well above current levels — with the average estimate around $358. That gap between analyst expectations and current price is part of why traders are watching for a rebound. Trading Recommendation: Putting it all together, I’m leaning LONG for a short-term bounce trade. The massive drawdown, modest bullish sentiment on X, and still-solid fundamentals create a setup where buyers may step in this week. Here’s my approach: I’d look for upside toward $336 first, with a stretch move toward $348 if momentum builds. Risk management matters here because sentiment isn’t fully aligned — so I’d keep stops tight around $314 and $304. Position sizing should stay moderate given the mixed signals and upcoming earnings volatility. If price breaks above the $335 area with volume, momentum traders could accelerate the move quickly.

Katy AI forecasts a sharp bearish reversal to $321.52 post-earnings, capitalizing on extreme overbought RSI (92.3) and low IV percentile despite recent Q1 beats raising the bar too high. Signal 🔴 BEARISH Alpha Score 72 (Quant Synthesis) # ⚡ QS V4 ELITE UNH (EARNINGS) * * | -------|:---------------| CORE THESIS Katy AI forecasts a sharp bearish reversal to $321.52 post-earnings, capitalizing on extreme overbought RSI (92.3) and low IV percentile despite recent Q1 beats raising the bar too high. ### ⬢ KATY AI EARNINGS VECTOR *Bias Bearish | Probability: 65% | Projected Move: -6.7% Tactical Observation Katy AI predicts bearish with 65% confidence, supported by overbought RSI (92.3) and put-heavy options flow (3 unusual puts, Put OI 32,773 vs. Call OI 48,113 despite 0.68 PCR), making a Bear Put Spread optimal to capture the projected downside while defining risk. STRATEGY BEAR PUT SPREAD | ALPHA EXPECTATION| | RISK GRADE 🚨 EXTREME (Binary Event) THESIS ERROR Earnings beat exceeding Katy AI projection with stock holding above $340 (upside surprise + IV crush) EXIT PROTOCOL Exit 100% at market open post-announcement to capture IV Crush or directional move. Risk Grade 🚨 EXTREME (Binary Event)

If you haven`t sold UNH near the top: Now analyzing the options chain and the chart patterns of UNH UnitedHealth Group Incorporated prior to the earnings report this week, I would consider purchasing the 350usd strike price at the money Calls with an expiration date of 2026-12-18, for a premium of approximately $23.70. If these options prove to be profitable prior to the earnings release, I would sell at least half of them.